<?xml version="1.0"?>
<!--<!DOCTYPE nitf SYSTEM "nitf-3-4.dtd">-->
<nitf>
  <head>
    <title id="Title">#Title</title>
    <docdata management-doc-idref="">
      <date.issue id="CreationDate" norm="" />
      <du-key id="rev-ver" generation="1" version="Default" />
      <du-key id="Parent-Version" version="" />
      <identified-content>
        <classifier id="newspro-nitf" value="r2" />
        <classifier id="Newspro-App" value="Epaper" />
        <classifier id="Content-Type" value="Story" />
        <classifier id="storyID" value="432312" />
        <classifier id="CmsConID" value="" />
        <classifier id="Desk" value="" />
        <classifier id="Source" value="" />
        <classifier id="Edition" value="" />
        <classifier id="Category" value="-1" />
        <classifier id="UserName" value="" />
        <classifier id="PublicationDate" value="26/10/2026" />
        <classifier id="PublicationName" value="DailyStar" />
        <classifier id="IsPublished" value="Y" />
        <classifier id="IsPlaced" value="Y" />
        <classifier id="IsCompleated" value="N" />
        <classifier id="IsProofed" value="N" />
        <classifier id="User" value="" />
        <classifier id="Headline-Count" value="" />
        <classifier id="Slug-Count" value="0" />
        <classifier id="Photo-Count" value="0" />
        <classifier id="Caption-Count" value="0" />
        <classifier id="Word-Count" value="0" />
        <classifier id="Character-Count" value="0" />
        <classifier id="Location" value="" />
        <classifier id="TemplateType" value="1" />
        <classifier id="StoryType" value="Story" />
        <classifier id="Author" value="" />
        <classifier id="UOM" value="mm" />
        <classifier id="kicker" value="" />
        <classifier id="ByLine" value="" />
        <classifier id="DateLine" value="" />
        <classifier id="box-geometry" value="695,117,971,1179" />
         <classifier id="Layer" value="Layer 1"/>
          <classifier id="numcol" value="1"/>
         <classifier id="ArticleStyle" value=""/>
       <classifier id="Epaper-Build" value="7.1.5.2"/>
  <classifier id="ProcessingDateTime" value="Sun Oct 25 2026 20:33:09 GMT+0600"/>
      </identified-content>

      <urgency id="home-page" ed-urg="0" />
      <urgency id="priority" ed-urg="0" />
      <doc-scope id="scope" value="0" />
    </docdata>
    <pubdata type="print" name="DailyStar" date.publication="20261026T000000+5.30" edition.name="Business" edition.area="BUS" position.section="DST26102604BUS-Bizback" position.sequence="4" ex-ref="DST26102604BUS-Bizback.indd" />
  </head>
  <body boxBorderWeightColor="#000000" boxBorderWeight="0.25">
<body.head>
      <hedline>
    	<hl1 id="Headline1" ul="0" ol="0" ulColor=""  ulWeight=""  olColor=""  olWeight="" textFrameColor="" orgstyle="HEAD new 25 MEDIUM" class="1" MainHead="true" style="Headline1">
		<lang class="3" colour="#000000" orgstyle="HEAD new 25 MEDIUM" style="Headline1"  font="Antonia H1" fontStyle="Medium" size="25">Pharma exports need stronger logistics to compete globally </lang>
	</hl1>

       </hedline>
</body.head>
    <body.content id="Bodytext" CaptionAsBody="0">
     <block>
	<media id="1" media-type="image">
		<media-reference id="tn" source-credit="" data-location="1" source="Syed_Ershad_Ahm_4_BUS_tn.jpg"  Units="pixels" width="50" height="50"></media-reference>
	</media>
</block>

     <p style=".Bodylaser" ul="0" ol="0"  orgstyle="BY NAME_2025">
	<lang class="3" style=".Bodylaser" colour="#000000" orgstyle="BY NAME_2025" font="Impact" fontStyle="Regular" size="9">▌</lang>
<lang  class="3" style=".Bodylaser" colour="#000000" orgstyle="BY NAME_2025" font="Antonia H1" fontStyle="Bold" size="9">	SYED ERSHAD AHMED
</lang>
</p>
<p style=".Bodylaser" ul="0" ol="0"  orgstyle="INDENTLESS BODY 2025">
	<lang class="3" style=".Bodylaser" colour="#000000" orgstyle="INDENTLESS BODY 2025" font="Antonia H1" fontStyle="Medium" size="9">The United States’ decision to apply a zero additional tariff rate to specified specialty pharmaceutical products and associated ingredients from Bangladesh presents a significant opportunity. The US Department of Commerce’s September 23 notice lists Bangladesh among the jurisdictions eligible for the zero Section 232 tariff rate on specified products, including orphan medicines, nuclear medicines, plasma-derived therapies, fertility drugs, cell and gene therapies, antibody-drug conjugates, certain medical countermeasures and animal health products.
</lang>
</p>
<p style=".Bodylaser" ul="0" ol="0"  orgstyle="BODY 2025">
	<lang class="3" style=".Bodylaser" colour="#000000" orgstyle="BODY 2025" font="Antonia H1" fontStyle="Medium" size="9">This development should be viewed not simply as a tariff issue, but as an opportunity to strengthen Bangladesh’s ability to serve a demanding global healthcare market. The exemption is product-specific and subject to US rules. Nevertheless, it reinforces the importance of developing a supply chain capable of protecting pharmaceutical quality from the factory to the final destination.
</lang>
</p>
<p style=".Bodylaser" ul="0" ol="0"  orgstyle="BODY 2025">
	<lang class="3" style=".Bodylaser" colour="#000000" orgstyle="BODY 2025" font="Antonia H1" fontStyle="Medium" size="9">Pharmaceutical logistics is fundamentally different from ordinary cargo movement. Some products can tolerate delays; many medicines, vaccines, biological materials and other temperature-sensitive products cannot. Their quality may depend on maintaining specified conditions throughout transportation, storage, handling and delivery. A shipment can leave a modern manufacturing plant in perfect condition and still be compromised by a temperature excursion, excessive exposure on the airport apron, inadequate storage or a poorly controlled handover. This is why Bangladesh needs to treat pharmaceutical logistics as a high-integrity supply chain, not merely an airport cargo function. The International Air Transport Association’s (IATA) pharmaceutical logistics standards emphasise temperature control, appropriate equipment and facilities, trained personnel, documentation, traceability, risk management and coordinated handling across the supply chain. Its CEIV Pharma programme provides a recognised framework covering infrastructure, equipment, quality management, training, warehousing, ground transportation and aircraft handling.
</lang>
</p>
<p style=".Bodylaser" ul="0" ol="0"  orgstyle="BODY 2025">
	<lang class="3" style=".Bodylaser" colour="#000000" orgstyle="BODY 2025" font="Antonia H1" fontStyle="Medium" size="9">For Bangladesh, an immediate priority should be developing dedicated pharmaceutical logistics capabilities at the country’s principal air cargo gateway. This should include validated temperature-controlled storage for different product requirements, rapid transfer between aircraft and storage, reliable backup power, temperature mapping and continuous monitoring, secure handling areas, calibrated sensors and clear procedures for temperature excursions.
</lang>
</p>
<p style=".Bodylaser" ul="0" ol="0"  orgstyle="BODY 2025">
	<lang class="3" style=".Bodylaser" colour="#000000" orgstyle="BODY 2025" font="Antonia H1" fontStyle="Medium" size="9">The system should also support active and passive temperature-controlled packaging, data loggers, appropriate unit load device handling and specialised vehicles so cargo is not unnecessarily exposed to ambient conditions. Dedicated fast-track procedures for customs clearance would further reduce dwell time. High-value and sensitive medicines require strong physical security, controlled access, accurate documentation and end-to-end shipment visibility.
</lang>
</p>
<p style=".Bodylaser" ul="0" ol="0"  orgstyle="BODY 2025">
	<lang class="3" style=".Bodylaser" colour="#000000" orgstyle="BODY 2025" font="Antonia H1" fontStyle="Medium" size="9">Training is equally important. Airlines, ground handlers, freight forwarders, customs personnel, warehouse operators and trucking companies should understand pharmaceutical handling procedures. Standard operating procedures and service-level agreements should define responsibilities at every handover. Digital tracking and electronic documentation can further strengthen traceability and reduce avoidable delays. IATA specifically identifies infrastructure, temperature monitoring, trained personnel, documentation, transportation and ground handling as important elements of pharmaceutical logistics. Singapore offers a useful benchmark. Its pharmaceutical and biomedical industries are supported by advanced manufacturing, global connectivity, regulatory capability and specialised logistics services. Bangladesh does not need to replicate Singapore, but it can learn from the principle that high-value healthcare manufacturing requires equally high-integrity logistics.
</lang>
</p>
<p style=".Bodylaser" ul="0" ol="0"  orgstyle="BODY 2025">
	<lang class="3" style=".Bodylaser" colour="#000000" orgstyle="BODY 2025" font="Antonia H1" fontStyle="Medium" size="9">The US tariff development therefore presents Bangladesh with more than a market-access opportunity. It is a reminder that competitive pharmaceutical exports depend on the entire supply chain. Investment in cold-chain infrastructure, trained personnel, secure cargo facilities, reliable power, digital monitoring and internationally aligned operating standards can help Bangladesh protect product integrity and build confidence among global buyers.
</lang>
</p>
<p style=".Bodylaser" ul="0" ol="0"  orgstyle="BODY 2025">
	<lang class="3" style=".Bodylaser" colour="#000000" orgstyle="BODY 2025" font="Antonia H1" fontStyle="Medium" size="9">For a country seeking to expand pharmaceutical exports, the next competitive advantage may not come only from what is manufactured inside the factory. It will also depend on how safely, quickly and reliably that product reaches the patient.
</lang>
</p>
<p style=".Bodylaser" ul="0" ol="0"  orgstyle="BODY 2025">
	<lang class="3" style=".Bodylaser" colour="#000000" orgstyle="BODY 2025" font="Antonia H1" fontStyle="Medium Italic" size="9">The writer is former president of FICCI and AmCham Bangladesh</lang>
</p>

<block id="subarticle1" boxBorderWeightColor="" boxBorderWeight="" style="subarticle" width="0" >

	<p style=".Bodylaser" ul="0" ol="0"  orgstyle="HIGHLIGHT 2025">
	<lang class="3" style=".Bodylaser" colour="#231f20" orgstyle="HIGHLIGHT 2025" font="Antonia H1" fontStyle="Bold" size="12">The next competitive advantage for Bangladesh’s pharmaceutical exports will depend on how safely, quickly and reliably medicines reach patients</lang>
</p>
<hl2 id="Headline2" class="1" style="Headline2">
		<lang class="3" style="Headline"  font=""  size=""></lang>
</hl2>
</block>
    </body.content>
  </body>
</nitf>